Non–industry-funded randomized controlled trial of Er:YAG vaginal laser to treat female stress urinary incontinence (reply to letter to the editor) - 07/10/25
Doi : 10.1016/j.ajog.2025.09.015
Patricia Lee, MD, CM, LLM 
Division of Urogynecology, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre
University of Toronto, Toronto, Ontario, Canada
Lesley Carr, MD
Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Rose Kung, MD, MSc
Division of Urogynecology, Department of Obstetrics and Gynecology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Sender Herschorn, MD, CM
Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Tuesday 07 October 2025
Le texte complet de cet article est disponible en PDF.
| S.H. has participated in clinical trials funded by AbbVie and Sumitomo Pharma (Urovant Sciences), is on the advisory board of AbbVie and Astellas Pharma, and has an unrestricted grant from Astellas Pharma. The other authors report no conflict of interest. |
|
| The trial was funded by an unrestricted grant from the Canadian Institutes of Health Research (Lee) and by local funding from the Temerty Faculty of Medicine at the University of Toronto and from the Department of Obstetrics and Gynecology at the University of Toronto for 2 research students (Perruzza and Kim). |
© 2025
Elsevier Inc. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?